Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

C. Monnerat,Roger Henriksson,T. Le Chevalier,S. Novello,P. Berthaud,S. Faivre,Eric Raymond

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

2004

C. Monnerat
Roger Henriksson
T. Le Chevalier
S. Novello
P. Berthaud
S. Faivre
Eric Raymond

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

Keywords:

Protein kinase A
Protein kinase C
Cancer
Pathology
Cisplatin
Antimetabolite
Medicine
Gemcitabine
Lung cancer
Staurosporine
Cell cycle

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations